



PRESS RELEASE

Transplantation Technologies announces name change to Trillium Therapeutics Inc. and arrival of Dr. Robert Uger as Director, Research & Development.

Toronto, Canada – May 13, 2003 - Transplantation Technologies Inc., a privately held biotechnology company specializing in the development of innovative therapies for the treatment of immune-mediated conditions, today announced that the new name, **Trillium Therapeutics Inc. (TTI)** was unanimously approved at its April 10 shareholders meeting. "While the previous name reflected the company's traditional interest in the field of transplantation, our current focus has expanded to include additional indications", explained the Company's chairman, Dr. Calvin Stiller. "The new name, Trillium Therapeutics, allows us to identify with the provincial flower of Ontario, which is a particularly appropriate symbol since the company is a result of the combined efforts of researchers at six Ontario-based academic institutions and hospitals."

TTI, which recently raised C\$7.5 million in a Series A financing led by the Vengrowth Advanced Life Sciences Fund, also announced that Dr. Robert Uger has joined the company as Director, Research & Development. "I would like to welcome Dr. Uger to his new position. We feel very fortunate to have such a strong and well rounded scientist as Bob to head up our R&D programs", commented new Chief Executive Officer, Dr. Niclas Stiernholm. "His leadership and interpersonal skills will greatly facilitate the process of building our scientific team".

TTI is a privately held Research and Development (R&D) company based in Toronto, Canada. The Company specializes in the development of innovative therapies aimed at restoring balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection and viral hepatitis. The Company's business model is to identify therapeutic candidates with promising efficacy profiles in animal models and to rapidly advance these into clinical testing. TTI is concentrating its activities on pre-clinical and early clinical development, with the primary objective of demonstrating safety and efficacy in humans.

May 13, 2003

The Company has two lead development candidates that it intends to advance into clinical testing, a CD200 fusion protein (CD200Fc) and an Fgl2-specific monoclonal antibody (Fgl2 Mab). In addition, it has several academic research agreements that provide access to world-class laboratories and a rich discovery pipeline. TTI has already established R&D collaborations with three major pharmaceutical and biotechnology companies, with the goal of developing these into future clinical/commercial partnerships.

- 30 -

For further information, please contact:

Niclas Stiernholm, Ph.D.
Chief Executive Officer
Trillium Therapeutics Inc.
700 Bay Street, Suite 2108
Toronto, Ontario, M5G 1Z6
Canada

Tel: (416) 595-0627
Fax: (416) 595-5835
niclas@trilliumtherapeutics.com
www.trilliumtherapeutics.com